Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin pretreatment before peginterferon alfa-2a plus ribavirin in untreated chronic hepatitis C genotype 1
2006-000935-86Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ribavirin and peginterferon alfa-2a in hepatitis C virus infection (3 arms), sponsored by Roche. Primary endpoints: Evaluation and comparison of HCV-RNA viral kinetic models and Comparison of treatment arms by kinetic parameters. Started Sep 2006; status: completed.
02
Drugs
ribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-000935-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000935-86.